Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
Early Phase Trials Unit; Department of Medicine.
S
S
Cousin
Early Phase Trials Unit; Department of Medicine.
M
M
Toulmonde
Department of Radiology.
M
M
Kind
Department of Nuclear Medicine.
A-L
AL
Cazeau
Department of Medicine.
D
D
Bechade
Department of Pathology, Institut Bergonié, Bordeaux, France.
J-M
JM
Coindre
Early Phase Trials Unit; Department of Medicine. Electronic address: a.italiano@bordeaux.unicancer.fr.
A
A
Italiano
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000000981:diagnostic imaging*
D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab